8-K: Applied DNA Sciences Announces $3.44 Million Registered Direct Offering

Applied DNA Sciences has entered into agreements for a $3.44 million registered direct offering of common stock and warrants.

Summary

• Applied DNA Sciences has announced a registered direct offering expected to raise approximately $3.4 million.
• The offering includes 3,228,056 shares of common stock and pre-funded warrants to purchase up to 2,416,005 shares.
• Concurrent with the offering, the company will issue unregistered warrants to purchase up to 11,288,122 shares of common stock.
• The offering is priced at $0.609 per share, with pre-funded warrants priced at $0.6089.
• The company will also reduce the exercise price of existing warrants to $0.609 and extend their expiration dates to August 2028, subject to shareholder approval.
• The offering is expected to close on or about February 2, 2024, pending customary closing conditions.

Sentiment

Score: 4

Explanation: The document is neutral to slightly negative. While the capital raise is positive for the company's operations, the dilution of existing shareholders and the company's history of losses temper the positive aspects. The risks associated with the company's technology and market position also contribute to the lower sentiment score.

Positives

• The capital raise will provide funds for the further development of the company's therapeutic DNA production services.
• The reduction of the exercise price and extension of the expiration dates of existing warrants may be seen as positive for warrant holders.
• The offering is priced at-the-market under Nasdaq rules.

Negatives

• The offering will dilute existing shareholders.
• The company has a history of net losses and limited financial resources.
• The company is dependent on future financing.

Risks

• The offering may not close.
• There is unknown future demand for the company's biotherapeutics products and services.
• There is inherent risk and unknown outcome of research and development projects.
• There is no guarantee of revenues and profits from the Linea DNA and/or Linea IVT platforms.
• There has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for human therapeutic use.

Future Outlook

The company intends to use the net proceeds from the offering for the further development of its therapeutic DNA production services, including the establishment of a fit-for-purpose manufacturing capacity for DNA critical starting materials for the manufacture of mRNA therapies, as well as general corporate purposes.

Management Comments

• The company has not provided any direct quotes from management in this document.

Industry Context

This offering comes as the biotechnology sector continues to see significant investment, particularly in companies focused on nucleic acid-based therapeutics. Applied DNA's focus on PCR-based DNA technologies and its recent acquisition of Spindle Biotech, Inc. positions it to capitalize on the growing demand for DNA and RNA production services.

Comparison to Industry Standards

• The at-the-market pricing of this offering is a common practice for companies seeking to raise capital without significantly impacting their share price.
• The use of pre-funded warrants is a strategy to allow investors to participate in the offering while managing their ownership limits.
• The reduction of exercise prices and extension of expiration dates for existing warrants is a common incentive to encourage warrant holders to exercise their options.
• Comparable companies in the biotechnology space, such as Moderna and BioNTech, have also raised capital through similar offerings to fund their research and development efforts.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Warrant holders will benefit from the reduction of exercise prices and extension of expiration dates.
• The company's employees may benefit from the increased funding for research and development.
• Customers may benefit from the further development of the company's therapeutic DNA production services.

Next Steps

• The company will close the offering on or about February 2, 2024.
• The company will seek shareholder approval for the reduction of exercise price and extension of expiration dates of existing warrants.
• The company will use the net proceeds for the further development of its therapeutic DNA production services and general corporate purposes.

Key Dates

Keywords

registered direct offering, common stock, warrants, pre-funded warrants, capital raise, DNA technologies, therapeutic DNA, mRNA therapies, biotechnology, PCR